Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET

Company Participants

Zach Weiner - Director of IR
Ivan Tornos - President and CEO
Suky Upadhyay - EVP, Finance, Operations and Supply Chain, and CFO

Conference Call Participants

David Roman - Goldman Sachs
Matt Taylor - Jefferies
Drew Ranieri - Morgan Stanley
Joanne Wuensch - Citi
Larry Biegelsen - Wells Fargo
Ryan Zimmerman - BTIG
Robbie Marcus - JPMorgan
Jayson Bedford - Raymond James
Josh Jennings - TD Cowen

Operator

Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Second Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, August 7, 2024. Following today's presentation, there will be a question-and-answer session. At this time, all participants are in a listen-only mode. [Operator Instructions]

I would now like to turn the conference over to Zach Weiner, Director of Investor Relations. Please go ahead.

Zach Weiner

Thank you, operator, and good morning, everyone. Welcome to Zimmer Biomet's second quarter 2024 earnings conference call. Joining me on today's call are Ivan Tornos, our President and CEO; and CFO and EVP, Finance, Operations, and Supply Chain, Suky Upadhyay.

Before we get started, I would like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties. Please note, we assume no obligation to update these forward-looking statements, even if actual results or future expectations change materially. Please refer to our SEC filing for a detailed discussion of these risks and uncertainties in addition to the inherent limitations of such forward-looking statements.

Additionally, the discussions on this call will include certain non-GAAP financial measures, some of which are forward-looking non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures and an explanation of our basis for calculating these measures is included within our second quarter earnings release, which can be found on our website, zimmerbiomet.com.

With that, I'll turn the call over to Ivan. Ivan?

Ivan Tornos

Thank you, Zach. Thank you, everyone, for joining today's call. Good morning.

I would like to start the way that I usually do, by taking a quick moment to show my sincere gratitude to the north of 18,000 Zimmer Biomet team members across the world, who each and every day go above and beyond in delivering on our mission, elevating pain and improving the quality of life for people around the world. That's what you and I get to do each and every day, and you're doing an unreal job in bringing this mission into action. Thank you for your commitment to Zimmer Biomet, thank you for your tireless work, and thank you for the very strong performance so far in this year 2024.